Exact Sciences’ Advanced Adenoma data ‘disappointing,’ says Stifel

Stifel analyst Daniel Arias tells investors in a research note that Exact Sciences reported BLUE-C results for Cologuard 2.0 ahead of the investor day event, demonstrating a 2% improvement in sensitivity to 94%, and a 4% improvement in specificity to 91%, compared to Cologuard 1.0. The analyst, who made no change to the firm’s Buy rating, says the BLUE-C read-out was in line with expectations from ASGO-GI, except in Advanced Adenoma, which was “a bit of a disappointment.”